SandboxAQ, a leader in quantitative AI for medical applications, has announced an expanded collaboration with Mayo Clinic to explore the combined use of electrocardiography (ECG) and magnetocardiography (MCG) using a quantum based sensor for monitoring amyloidosis, a condition characterized by abnormal protein buildup in organs, including the heart. The partnership aims to develop a non-invasive diagnostic solution that integrates ECG’s reliability with MCG’s sensitivity due to the quantum based sensing technology it uses. This enables earlier detection of cardiac changes and improved tracking of disease progression and treatment response.
The collaboration builds on ongoing research at Mayo Clinic in Rochester, Minnesota, where SandboxAQ’s MCG device and AI are being tested. The new initiative will focus on joint studies to evaluate the feasibility of the combined ECG-MCG approach, with potential applications for other cardiac conditions requiring precise, non-invasive diagnostics.
Jack Hidary, CEO of SandboxAQ, emphasized the partnership’s potential to revolutionize diagnostic accuracy and patient care, while Kit Yee Au-Yeung, GM of SandboxAQ’s AQMed division, highlighted the synergy between SandboxAQ’s innovation and Mayo Clinic’s clinical expertise.
For more information, visit SandboxAQ’s AQMed solutions page here and the press release here.
January 17, 2025
Leave A Comment